Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis

被引:0
作者
Lan Huang
Qiao-Rong Dong
Ya-Juan Zhao
Gui-Cai Hu
机构
[1] Affiliated Hospital of Chengde Medical University,Division of Nephrology
来源
International Urology and Nephrology | 2021年 / 53卷
关键词
Membranous nephropathy; Rituximab; CD20 antibody; Immunosuppression; Remission;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:111 / 119
页数:8
相关论文
共 376 条
[1]  
Ruggenenti P(2017)Treatment of membranous nephropathy: time for a paradigm shift Nat Rev Nephrol 13 563-579
[2]  
Fervenza FC(2014)Glomerular diseases: membranous nephropathy–a modern view Clin J Am Soc Nephrol 9 609-616
[3]  
Remuzzi G(2017)Primary membranous nephropathy [correction in: Clin J Am Soc Nephrol] Clin J Am Soc Nephrol 12 983-997
[4]  
Ponticelli C(2011)The incidence of primary glomerulonephritis worldwide: a systematic review of the literature Nephrol Dial Transplant 26 414-430
[5]  
Glassock RJ(1980)In situ immune complex formation and glomerular injury Kidney Int 17 1-13
[6]  
Couser WG(2009)M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy N Engl J Med 361 11-21
[7]  
McGrogan A(2014)Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy N Engl J Med 371 2277-2287
[8]  
Franssen CF(2016)Membranous nephropathy: a journey from bench to bedside Am J Kidney Dis 68 138-147
[9]  
de Vries CS(2015)Drug-induced glomerular disease: immune-mediated injury Clin J Am Soc Nephrol 10 1300-1310
[10]  
Couser WG(2016)Long-term exposure to air pollution and increased risk of membranous nephropathy in China J Am Soc Nephrol 27 3739-3746